ZTA Biotech team develops ELISA protocol for COVID-19 IgG antibody detection
Image by Shutterstock.com
ZTA Biotech, a Budapest-based biotech startup has announced the breakthrough development of a COVID-19 antibody (IgG) test using the ELISA protocol.
This new detection method represents a step forward in determining if patients have had COVID-19 and if they might still have immunity to the disease. Early results have proven 100% in specificity after testing 280 samples, and 100% sensitivity by testing 260 samples of recovered and symptomatic patients, according to a press release sent to the Budapest Business Journal.
With a potential market of 5.8 billion people, the formula has a massive potential across the globe, the press release notes. ZTA Biotech is currently offering the intellectual property rights to licensees and/or to a sole-rights purchaser, in order to help bring this breakthrough ELISA formula to market.
The presented ELISA (Enzyme Linked Immunosorbent Assay) protocol is designed for the intended use in the post-vaccination period that is soon to commence (first/second trimester of 2021). Its microplates are coated with critical antigens which are the prime targets of the current vaccine developments (of any kind). The kit can also be used to monitor past, natural exposure to SARS-CoV-2 and to evaluate the possibility of re-infection.
The test is based on selective detection of human IgG antibodies that bind to SARS- CoV-2 antigens coated on the wells of the microplate and can be used for qualitative and semi-quantitative determination of human IgG. After the completion of the first critical reaction step, all unbound serum components are fully washed away and a series of reactions occur that will lead to a photometrically measurable step where the intensity of the obtained color is proportional to the quantity of SARS-CoV-2 IgG antibodies in the original sample. The whole process takes less than two hours to complete and can be fully automated.
The test was independently validated, with a sensitivity of 100% and a specificity of 100%, and compared to an approved test of a major test producer, the latter being outperformed. All testing for validation was carried out on samples collected between September 2019 – June 2020. The antibody test showed extremely low background noise. All sensitivity evaluation data was based on PCR tested, positive SARS-CoV-2 patients, all symptomatic after getting infected. No cross-reactivity was observed to SARS-CoV-2 IgM.
The kit has a long shelf life and opened kits are usable for up to three months at storing temperatures of 5°C, the press release notes.
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.